In our case, the decision to omit chemotherapy was informed by the tumor’s MMR-deficient profile (loss of MLH1 and PMS2), stage IIA classification (T4N0M0), and the absence of additional high-risk features beyond lymphovascular invasion [7,8,9]. This evidence concerns the gene MLH1 and neoplasm.